Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUSERPIN vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension,Psychotic disorders (off-label),Schizophrenia (off-label)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
250 mg orally twice daily
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hepatic via CYP2D6; undergoes extensive first-pass metabolism; metabolites excreted in urine and feces.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
80-90% bound primarily to albumin
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.0-2.0 L/kg; clinical meaning: indicates extensive tissue distribution, including CNS.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 80-90%; Intramuscular: 100%
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: reduce dose by 25%. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: avoid use.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 0.05 mg orally once daily; increase slowly. Maximum 1.5 mg/day. Monitor for orthostatic hypotension and sedation.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA black box warning.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause severe depression with high risk of suicide,Electroconvulsive therapy (ECT) should be discontinued at least 7 days prior,Use cautiously in patients with history of peptic ulcer disease (increased gastric acid secretion),May precipitate biliary colic in patients with gallstones,Monitor for hypotension and bradycardia
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to rauwolfia alkaloids,History of mental depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Pheochromocytoma,Concomitant use with MAO inhibitors
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, pickled fish, ferments) as RAUSERPIN may potentiate their pressor effects, leading to hypertensive crisis. Limit alcohol intake due to increased risk of hypotension and sedation.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; human data limited but avoid use. Second and third trimesters: Fetal bradycardia, hypothermia, and respiratory depression due to catecholamine depletion. Neonatal withdrawal: Lethargy, nasal congestion, and poor feeding. Avoid use throughout pregnancy.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk with an M/P ratio of approximately 1.0. Potential for significant effects in the nursing infant including bradycardia, sedation, and gastrointestinal disturbances. Use is contraindicated during breastfeeding.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Plasma volume expansion in pregnancy may reduce reserpine concentrations. No established dose adjustment guidelines; clinical response monitoring is recommended. Avoid due to fetal risks. If unavoidable, use lowest effective dose and frequent monitoring.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
RAUSERPIN (rauwolfia alkaloid) is an antihypertensive that depletes catecholamines from postganglionic sympathetic nerve endings. Onset of effect is slow (weeks), and it may cause significant bradycardia and sedation. Avoid in patients with history of depression, peptic ulcer disease, or pheochromocytoma. Use with caution in patients receiving MAOIs or other antihypertensives due to additive effects.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily at the same time each day.,It may take several weeks to see the full benefit; do not stop abruptly as this may cause rapid increase in blood pressure.,This drug may cause drowsiness, dizziness, or nasal congestion; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and sedatives as they may worsen drowsiness.,Contact your doctor if you experience depression, slow heart rate, fainting, or signs of stomach ulcer (e.g., black stools, stomach pain).
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUSERPIN vs ALDOCLOR-250, answered by our medical review team.
RAUSERPIN is a Antihypertensive that works by Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUSERPIN and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUSERPIN is: Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUSERPIN and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUSERPIN is classified as Category C. Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; hum. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.